Neurol. praxi. 2024;25(2):130-134 | DOI: 10.36290/neu.2024.009

Tapentadol hydrochloride in treating acute and chronic pain

MUDr. Marek Hakl, Ph.D.
Centrum léčby bolesti, Brno
Medicinecare, s. r. o., Brno

Tapentadol hydrochloride is a novel, potent opioid analgesic that is classified as an atypical opioid. The principle of action consists not only in binding to opioid receptors, but also in affecting noradrenaline reuptake. This lends the drug unique properties. It has a very good effect in neuropathic pain, with an outstandingly low rate of adverse effects. Due to its low binding to plasma proteins and bypassing the CYP450 system, tapentadol hydrochloride is only minimally involved in drug interactions. Tapentadol hydrochloride is available both in retarded release formulation and in formulations with a rapid onset of action.

Keywords: tapentadol hydrochloride, acute pain, chronic pain, safety, adverse effects, neuropathic pain.

Received: January 21, 2024; Revised: January 21, 2024; Accepted: February 2, 2024; Prepublished online: February 2, 2024; Published: April 16, 2024  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Hakl M. Tapentadol hydrochloride in treating acute and chronic pain. Neurol. praxi. 2024;25(2):130-134. doi: 10.36290/neu.2024.009.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Breivik H, Collett B, Ventafridda V, et al. Survey of chronic pain in Europe: Prevalence, impact on daily life, and treat­ment. Eur J Pain. 2006;10:287-333. Go to original source... Go to PubMed...
    2. Müller­‑Schwefe G. Make a CHANGE: optimising communications and pain management decisions. Curr Med Res Opin. 2011;2:481-488. Go to original source... Go to PubMed...
    3. Skála B. Doporučené postupy pro farmakoterapii bolesti a jejich dopad v oblasti primární péče. Bolest. 2008;3:151-155.
    4. Schröder W, Vry JD, Tzschentke TM, et al. Differential contribution of opioid and noradrenergic mechanisms of tapentadol in rat models of nociceptive and neuropathic pain. Eur J Pain. 2010;14(8):814-821. Go to original source... Go to PubMed...
    5. Kozák J, et al. Metodické pokyny pro farmakoterapii bolesti - speciální část. Supplementum. 2023;1:1.
    6. Vránová V. Tapentadol hydrochlorid - inovativní atypický opioid s unikátním mechanismem účinku. Remedia. 2023;33(4):31-35.

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.